Lab Babble: Today's fact, tomorrow's retract
You can withdraw a discredited paper, but the long tail of citations lingers on and on, cautions Russ Swan.
Stay updated with breaking news from Primary Prevention. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
You can withdraw a discredited paper, but the long tail of citations lingers on and on, cautions Russ Swan.
At ADA 2023, we asked interview guests for their opinions on the most important news to come from this year's scientific sessions, including Juan Frias, MD, Bob Gabbay, MD, PhD, Yehuda Handelsman, MD, Viral Shah, MD, and more.
An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary...
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause